GENERAL CLINICAL RESEARCH CENTER

德克萨斯大学健康科学临床研究中心 中心和赫尔曼医院提供了一个独特的环境， 调查UT医学院和UT M.D.安德森 癌症中心认识到这一点的优势和重要性， 多学科设施，提供细致的控制 实验条件，生物现象的准确监测，以及 正确收集和处理有价值的标本。主要研究 这些领域将包括： 1. 人巨噬细胞对纤维化反应的功能分析 微粒 2. 177-Lu-CC 49联合α干扰素治疗晚期乳腺癌的临床观察 或复发性卵巢癌。 3. 家族性高血压的遗传分子因素分析 主动脉瘤 4. 用rIFN γ腹膜内预充，然后用rIL-2离体预充 免疫治疗中活化的肿瘤浸润淋巴细胞的扩增 卵巢上皮癌 5. HIV对血友病患者生长发育的影响 儿童、青少年和年轻人。 6. 微小隐孢子虫感染机制的研究 对于成年人来说。 7. 弥漫性浸润性淋巴细胞增多综合征的特征 （DILS）及其在HIV感染患者中的预后。 8. 人类基因治疗和安全性改良逆转录病毒的使用 为了在化疗期间引入用于化学保护的化疗抗性序列， 卵巢癌的治疗 在我们的临床研究中心（CRC），我们希望进行有意义的 阐明人类疾病基本机制的临床研究 疾病导致改进的疗法。我们希望解决重要的 影响儿童和成人的疾病和疾病过程， 期望我们的研究提供的新见解将有助于 根除和预防严重的医疗问题。我们的CRC将 联合收割机临床研究成果在得克萨斯大学医学 学校和德克萨斯大学医学博士。安德森癌症中心， 休斯顿我们预计，这种联合研究工作将导致新的 基于机制的疗法，帮助治愈并最终预防选择性的 医学疾病。

The Clinical Research Center at the University of Texas Health Science Center and Hermann Hospital provides a unique environment for clinical investigation. The faculty of the UT Medical School and UT M.D. Anderson Cancer Center appreciate the advantage and importance of having this multidisciplinary facility which provides meticulous control of experimental conditions, accurate monitoring of biologic phenomena, and proper collection and handling of valuable specimens. Major research areas will include: 1. Analysis of human macrophage function in response to fibrogenic particulates. 2. Use of 177-Lu-CC49 plus alpha interferon in patients with advanced or recurrent ovarian cancer. 3. Elucidation of genetic molecular factors responsible for familial aortic aneurysms. 4. Intraperitoneal priming with rIFNgamma followed by rlL-2 for ex vivo expansion of activated tumor infiltrating lymphocytes in immunotherapy of epithelial ovarian cancer. 5. Elucidation of effects of HIV on growth and development of hemophilic children, adolescents, and young adults. 6. Elucidation of mechanisms of infectivity of Cryptosporidium parvum for adult humans. 7. Characterization of diffuse infiltrating lymphocytosis syndrome (DILS) and its prognosis in patients with HIV infection. 8. Gene therapy in humans and the use of safety-modified retroviruses to introduce chemotherapy resistance sequences for chemoprotection during the therapy of ovarian cancer In our Clinical Research Center (CRC), we wish to conduct meaningful clinical research that elucidate basic mechanisms responsible for human disease leading to improved therapies. We wish to address important diseases and disease processes that affect children and adults with the expectation that the new insights our research provides will contribute to eradication and prevention of serious medical problems. Our CRC will combine clinical research efforts at the University of Texas Medical School and the University of Texas M.D. Anderson Cancer Center at Houston. We anticipate that this combined research effort will lead o new mechanism based therapies that help cure and ultimately prevent selected medical diseases.